drugset / Trial / NCT00247273

A Study of Monthly Risedronate for Osteoporosis

NCT00247273

Phase 3 Completed 1294 enrolled Warner Chilcott Sanofi · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

Timeline

Start
2005-10
Primary completion
2008-03
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Risedronate Small molecule 5 mg Oral
Subject Risedronate Small molecule 150 mg Oral